Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple Negative Breast Cancer.
CONCLUSIONS: The combination of carboplatin and nab-paclitaxel for early stage high risk TNBC showed manageable toxicity and encouraging anti-tumor activity. GSIS "immune-hot" signature is associated with higher pCR rate and RCB class 0/1. This study provides additional rationale for using non-anthracycline platinum-based therapy for future neoadjuvant trials in early stage TNBCs.
IMPLICATIONS FOR PRACTICE: Platinum is an important neoadjuvant chemotherapy agent for treatment of early stage triple negative breast cancer (TNBC). In this study, carboplatin and nab-paclitaxel were well tolerated and highly effective in TNBC, resulting in pathological complete response of 48%. In univariate and multivariate analyses adjusting for age, race, tumor stage and grade, "immune-hot" GeparSixto Immune Signature (GSIS) and DNA repair defect were associated with higher pCR and residual cancer burden class 0/1. The association of GSIS "immune-hot" signature with higher pCR holds promise for "de-escalating" neoadjuvant chemotherapy for patients with early stage TNBC. Although GSIS is not routinely used in clinic, further development of this immune signature into a clinically applicable assay is indicated.
PMID: 33098195 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Yuan Y, Lee JS, Yost SE, Li SM, Frankel PH, Ruel C, Schmolze D, Robinson K, Tang A, Martinez N, Stewart D, Waisman J, Kruper L, Jones V, Menicucci A, Uygun S, Yoder E, van der Baan B, Yim JH, Yeon C, Somlo G, Mortimer J Tags: Oncologist Source Type: research
More News: Anemia | Brain | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Gastroschisis Repair | Men | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Neurology | Neurosurgery | Peripheral Neuropathy | Study | Thrombocytopenia | Toxicology